<DOC>
	<DOCNO>NCT00468286</DOCNO>
	<brief_summary>The study two treatment group , evaluate two Degarelix dos . First dose initial dose follow maintenance dose give every three month . The initial dose give suppress testosterone level three month maintenance dose maintain suppress testosterone level one year treatment .</brief_summary>
	<brief_title>Investigating Efficacy Safety Two Degarelix Three-Month Dosing Regimens Patients With Prostate Cancer Requiring Androgen Ablation Therapy</brief_title>
	<detailed_description>An Open-Label , Multi-Centre , Randomized Parallel-Group Dose-Finding Study , Investigating Efficacy Safety Two Degarelix Three-Month Dosing Regimens Patients Prostrate Cancer Requiring Androgen Ablation Therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion / Patients , age 18 year old , histologically proven prostate cancer stag endocrine treatment indicate . Screening testosterone level lower limit normal range , globally define &gt; 2.2 ng/mL . Eastern Cooperative Oncology Group ( ECOG ) score ≤2 . Screening prostatespecific antigen ( PSA ) level ≥ ng/mL .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>